The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Treatment of Polymyalgia Rheumatica: A Systematic Review
Abstract
BACKGROUND: Polymyalgia rheumatica (PMR) treatment is based on low-dose glucocorticoids. Glucocorticoid-sparing agents have also been tested. Our objective was to systematically examine the peer-reviewed literature on PMR therapy, particularly the optimal glucocorticoid type, starting doses, and subsequent reduction regimens as well as glucocorticoid-sparing medications. METHODS: We searched Cochrane Databases and MEDLINE (1957 through December 2008) for English-language articles on PMR treatment (randomized trials, prospective cohorts, case-control trials, and case series) that included 20 or more patients. All data on study design, PMR definition criteria, medical therapy, and disease outcomes were collected using a standardized protocol. RESULTS: Thirty studies (13 randomized trials and 17 observational studies) were analyzed. No meta-analyses or systematic reviews were found. The PMR definition criteria, treatment protocols, and outcome measures differed widely among the trials. Starting prednisone doses higher than 10 mg/d were associated with fewer relapses and shorter therapy than were lower doses; starting prednisone doses of 15 mg/d or lower were associated with lower cumulative glucocorticoid doses than were higher starting prednisone doses; and starting prednisone doses higher than 15 mg/d were associated with more glucocorticoid-related adverse effects. Slow prednisone dose tapering (<1 mg/mo) was associated with fewer relapses and more frequent glucocorticoid treatment cessation than faster tapering regimens. Initial addition of oral or intramuscular methotrexate provided efficacy at doses of 10 mg/wk or higher. Infliximab was ineffective as initial cotreatment. CONCLUSIONS: The scarcity of randomized trials and the high level of heterogeneity of studies on PMR therapy do not allow firm conclusions to be drawn. However, PMR remission seems to be achieved with prednisone treatment at a dose of 15 mg/d in most patients, and reductions below 10 mg/d should preferably follow a tapering rate of less than 1 mg/mo. Methotrexate seems to exert glucocorticoid-sparing properties.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although the efficacy of these doses on disease activity in various conditions is well established [1–4, 7]”
From Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: a randomised controlled trial (2011) · cites this paper as [2]
In the citing paper
“Glucocorticoids (GCs) are the cornerstone in the treatment of numerous chronic autoimmune and inflammatory diseases, including rheumatoid arthritis [1], polymyalgia rheumatica [2] and giant cell arteritis [3], systemic lupus erythematosus [4] and inflammatory bowel diseases [5].”
From Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: a randomised controlled trial (2011) · cites this paper as [2]
Citations
Cites
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040296 · Cited by 23,020
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-8-200710160-00010 · Cited by 17,796
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Sanderson, S., Tatt, I. D., & Higgins, J. P. (2007) · International Journal of Epidemiology · doi:10.1093/ije/dym018 · Cited by 1,531
Polymyalgia Rheumatica and Giant-Cell Arteritis
Salvarani, C., Cantini, F., Boiardi, L., & Hunder, G. G. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011913 · Cited by 1,352
Polymyalgia Rheumatica and Giant Cell Arteritis
Ettlinger, R. E., Hunder, G. G., & Ward, L. E. (1978) · Annual Review of Medicine · doi:10.1146/annurev.me.29.020178.000311 · Cited by 687
An evaluation of criteria for polymyalgia rheumatica.
Bird, H. A., Esselinckx, W., Dixon, A. S., Mowat, A. G., & Wood, P. H. (1979) · Annals of the Rheumatic Diseases · doi:10.1136/ard.38.5.434 · Cited by 490
HUSKISSON, E. C., & HART, F. D. (1987) · Joint Disease · doi:10.1016/b978-0-7236-0571-3.50187-7 · Cited by 436
Angeli, A., Guglielmi, G., Dovio, A., Capelli, G., de Feo, D., Giannini, S., Giorgino, R., Moro, L., & Giustina, A. (2006) · Bone · doi:10.1016/j.bone.2006.02.005 · Cited by 365
Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study.
De Silva, M., & Hazleman, B. L. (1986) · Annals of the Rheumatic Diseases · doi:10.1136/ard.45.2.136 · Cited by 360
Long-term follow-up of polymyalgia rheumatica: Evidence for synovitis
Healey, L. A. (1984) · Seminars in Arthritis and Rheumatism · doi:10.1016/0049-0172(84)90012-x · Cited by 307
Temporal Arteritis and Polymyalgia Rheumatica: Clinical and Biopsy Findings
FAUCHALD, P., RYGVOLD, O., & ØYSTESE, B. (1972) · Annals of Internal Medicine · doi:10.7326/0003-4819-77-6-845 · Cited by 298
Prognosis and management of polymyalgia rheumatica.
Jones, J. G., & Hazleman, B. L. (1981) · Annals of the Rheumatic Diseases · doi:10.1136/ard.40.1.1 · Cited by 276
Caporali, R., Cimmino, M. A., Ferraccioli, G., Gerli, R., Klersy, C., Salvarani, C., Montecucco, C., & for the Systemic Vasculitis Study Group of the Italian Society for Rheumatology (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-7-200410050-00005 · Cited by 261
Kimpel, D. L. (2009) · Yearbook of Medicine · doi:10.1016/s0084-3873(09)79348-4 · Cited by 251
Myalgic Syndrome with Constitutional Effects
Barber, H. S. (1957) · Annals of the Rheumatic Diseases · doi:10.1136/ard.16.2.230 · Cited by 246
Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica
Gabriel, S. E., Sunku, J., Salvarani, C., O'Fallon, W. M., & Hunder, G. G. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780401022 · Cited by 239
van der Veen, M. J., Dinant, H. J., van Booma-Frankfort, C., van Albada-Kuipers, G. A., & Bijlsma, J. W. (1996) · Annals of the Rheumatic Diseases · doi:10.1136/ard.55.4.218 · Cited by 212
Salvarani, C., Macchioni, P., Manzini, C., Paolazzi, G., Trotta, A., Manganelli, P., Cimmino, M., Gerli, R., Catanoso, M. G., Boiardi, L., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-9-200705010-00005 · Cited by 199
Delecoeuillerie, G., Joly, P., Cohen de Lara, A., & Paolaggi, J. B. (1988) · Annals of the Rheumatic Diseases · doi:10.1136/ard.47.9.733 · Cited by 181
Salvarani, C., Cantini, F., Niccoli, L., Macchioni, P., Consonni, D., Bajocchi, G., Vinceti, M., Catanoso, M. G., Pulsatelli, L., Meliconi, R., et al. (2005) · Arthritis Care & Research · doi:10.1002/art.20901 · Cited by 160
Kyle, V., & Hazleman, B. L. (1989) · Annals of the Rheumatic Diseases · doi:10.1136/ard.48.8.658 · Cited by 151
Hutchings, A., Hollywood, J., Lamping, D. L., Pease, C. T., Chakravarty, K., SILVERMAN, B. G., Choy, E., Scott, D. G. I., Hazleman, B. L., Bourke, B., et al. (2007) · Arthritis Care & Research · doi:10.1002/art.22777 · Cited by 149
González-Gay, M. Á., Garcı́a-Porrúa, C., Vázquez‐Caruncho, M., et al. (1999) · PubMed · Cited by 147
Relapse in a population based cohort of patients with polymyalgia rheumatica.
Kremers, H. M., Reinalda, M. S., Crowson, C. S., Zinsmeister, A. R., Hunder, G. G., & Gabriel, S. E. (2005) · PubMed · Cited by 145
Corticosteroid Requirements in Polymyalgia Rheumatica
Weyand, C. M., Fulbright, J. W., Evans, J. M., et al. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.6.577 · Cited by 118
Polymyalgia rheumatica. Duration of therapy and long-term outcome
Ayoub, W. T., Franklin, C., & Torretti, D. (1985) · The American Journal of Medicine · doi:10.1016/0002-9343(85)90309-2 · Cited by 117
Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study.
Ferraccioli, G., Salaffi, F., Vita, S. D., et al. (1996) · PubMed · Cited by 116
Dasgupta, B., Dolan, A. L., Panayi, G. S., et al. (1998) · Lara D. Veeken · doi:10.1093/rheumatology/37.2.189 · Cited by 112
Polymyalgia rheumatica and corticosteroids: how much for how long?
Behn, A. R., Perera, T., & Myles, A. B. (1983) · Annals of the Rheumatic Diseases · doi:10.1136/ard.42.4.374 · Cited by 94
Dasgupta, B., Salvarani, C., Schirmer, M., Crowson, C. S., Kremers, H. M., Hutchings, A., & Matteson, E. L. (2008) · PubMed · Cited by 93
Wegrzyn, J., Adeleine, P., & Miossec, P. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.011593 · Cited by 81
Myklebust, J. T. G. G. (2001) · Scandinavian Journal of Rheumatology · doi:10.1080/030097401753180327 · Cited by 81
Prognosis in the Anarthritic Rheumatoid Syndrome
Bagratuni, L. (1963) · BMJ · doi:10.1136/bmj.1.5329.513 · Cited by 80
Kyle, V., & Hazleman, B. L. (1993) · Annals of the Rheumatic Diseases · doi:10.1136/ard.52.12.847 · Cited by 79
Leeb, B. F., Bird, H. A., Nesher, G., et al. (2003) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2002.002618 · Cited by 70
Long-term follow-up of polymyalgia rheumatica patients treated with methotrexate and steroids.
Cimmino, M. A., Salvarani, C., Macchioni, P., Gerli, R., Bocci, E. B., Montecucco, C., & Caporali, R. F. (2008) · PubMed · Cited by 63
The polymyalgia rheumatica activity score in daily use: Proposal for a definition of remission
Leeb, B. F., Rintelen, B., Sautner, J., Fassl, C., & Bird, H. A. (2007) · Arthritis Care & Research · doi:10.1002/art.22771 · Cited by 58
Longterm therapy in polymyalgia rheumatica: effect of coexistent temporal arteritis.
Narváez, J., Nolla-Solé, J. M., Clavaguera, T., et al. (1999) · PubMed · Cited by 52
Hernández‐Rodríguez, J., Font, C., García‐Martínez, A., et al. (2007) · Medicine · doi:10.1097/md.0b013e318145275c · Cited by 48
Self-citationSalvarani, C., Cantini, F., Olivieri, I., et al. (2000) · PubMed · Cited by 46
Is the Course of Steroid‐Treated Polymyalgia Rheumatica More Severe in Women?
Cimmino, M. A., PARODI, M., Caporali, R. F., & Montecucco, C. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1351.030 · Cited by 40
Long-term follow-up of polymyalgia rheumatica.
Spiera, H., & Davison, S. (1978) · PubMed · Cited by 36
The use of methotrexate in polymyalgia rheumatica.
Feinberg, H. L., Sherman, J. D., Schrepferman, C. G., et al. (1996) · PubMed · Cited by 33
Krogsgaard, M. R., Lund, B., & Johnsson, B. (1995) · PubMed · Cited by 33
Long term treatment of polymyalgia rheumatica with deflazacort.
Cimmino, M. A., Moggiana, G., Montecucco, C., et al. (1994) · Annals of the Rheumatic Diseases · doi:10.1136/ard.53.5.331 · Cited by 30
Di Munno, O., Imbimbo, B. P., Mazzantini, M., et al. (1995) · PubMed · Cited by 26
Esselinckx, W., Doherty, S. M., & Dixon, A. S. J. (1977) · Annals of the Rheumatic Diseases · doi:10.1136/ard.36.3.219 · Cited by 22
Lund, B. V., Egsmose, C., Jørgensen, F. S., et al. (1987) · Calcified Tissue International · doi:10.1007/bf02556669 · Cited by 21
Littman, B. H., BJARNASON, D., Bryant, G., et al. (1995) · PubMed · Cited by 18
Cited by
Brahmer, J. R., Abu-Sbeih, H., Ascierto, P. A., Brufsky, J., Cappelli, L. C., Cortazar, F. B., Gerber, D. E., Hamad, L., Hansen, E., Johnson, D. B., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002435 · Cited by 917
Paraneoplastic Syndromes: An Approach to Diagnosis and Treatment
Pelosof, L. C., & Gerber, D. E. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0099 · Cited by 773
Dasgupta, B., Cimmino, M. A., Maradit-Kremers, H., Schmidt, W. A., Schirmer, M., Salvarani, C., Bachta, A., Dejaco, C., Duftner, C., Jensen, H. S., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-200329 · Cited by 673
Dasgupta, B., Cimmino, M. A., Kremers, H. M., Schmidt, W. A., Schirmer, M., Salvarani, C., Bachta, A., Dejaco, C., Duftner, C., Jensen, H. S., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34356 · Cited by 413
Dejaco, C., Singh, Y. P., Perel, P., Hutchings, A., Camellino, D., Mackie, S., Abril, A., Bachta, A., Balint, P., Barraclough, K., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-207492 · Cited by 334
Metadata
- Authors
- Hernández-Rodríguez, J.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2009-11-09
- Volume
- 169
- Issue
- 20
- Pages
- 1839
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W1967784397
- Cited by
- 118
- References
- 50
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 6 · 2023: 3 · 2022: 3 · 2021: 4 · 2020: 6 · 2019: 4 · 2018: 6 · 2017: 9 · 2016: 4 · 2015: 11 · 2014: 6 · 2013: 18 · 2012: 18
- FWCI
- 9.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Archives of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Vasculitis and related conditions
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Health Sciences › Medicine › Rheumatology › Otitis Media and Relapsing Polychondritis
- Keywords
- polymyalgia rheumatica, prednisone, glucocorticoid dose, glucocorticoid tapering, glucocorticoid-sparing agents, methotrexate, infliximab, relapse, glucocorticoid adverse effects, treatment discontinuation
- MeSH terms
- Aged, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Glucocorticoids, Humans, Long-Term Care, Male, Middle Aged, Pain Measurement, Polymyalgia Rheumatica, Prednisone, Quality of Life, Severity of Illness Index, Case-Control Studies, Randomized Controlled Trials as Topic, Treatment Outcome, Patient Satisfaction, Risk Assessment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.